Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
The obesity treatment pipeline is rapidly evolving, with promising candidates such as RGT-075 (Regor Therapeutics), MET-002o (D&D Pharmatech/Pfizer), enicepatide (CT-388; Roche/Carmot Therapeutics), elecoglipron (AstraZeneca), and several other emerging therapies advancing next-generation...
Covered in this story
What has happened since
- MetLife is up 2.1% since this was published, 43 days ago.
- Pfizer is up 8.6% since this was published, 43 days ago.
- AstraZeneca is up 9.1% since this was published, 43 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on MetLife
- Evercore ISI: $96.2 → $106 by Aug 2027 · In Line via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MET yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on MetLife →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.